Table 2.
The levels of calprotectin, ANGPTL8, and oxidative damage to nucleic acids in patients and controls with and without MetS.
| Parameter | Q1 | Median | Q3 | Geometric mean | Min | Max | Significance of the differences |
|---|---|---|---|---|---|---|---|
| Calprotectin (pg/mL) | |||||||
| Patients No-MetS | 4298.0 | 4746.0 | 7233.8 | 5746.0 | 1976.0 | 12538.0 | NS |
| Patients MetS | 4020.3 | 5612.5 | 8590.8 | 6310.3 | 1360.0 | 12800.0 | |
| Controls No-MetS | 1185.8 | 1690.5 | 2334.0 | 1964.5 | 497.0 | 6299.0 | NS |
| Controls MetS | 1389.3 | 2232.5 | 2984.5 | 2358.7 | 779.0 | 5659.0 | |
| ANGPTL8 (ng/mL) | |||||||
| Patients No-MetS | 10.78 | 13.80 | 19.00 | 14.70 | 5.78 | 25.50 | NS |
| Patients MetS | 10.98 | 13.92 | 19.98 | 14.74 | 4.60 | 24.30 | |
| Controls No-MetS | 10.02 | 12.20 | 15.09 | 12.63 | 2.30 | 25.40 | NS |
| Controls MetS | 9.47 | 11.75 | 15.60 | 12.98 | 2.10 | 32.80 | |
| Oxidative damage to nucleic acids (pg/mL) | |||||||
| Patients No-MetS | 2004 | 2931 | 4506 | 3415 | 700 | 8150 | NS |
| Patients MetS | 2270 | 3517 | 4523 | 3651 | 500 | 13050 | |
| Controls No-MetS | 1250 | 1805 | 3612 | 2665 | 191 | 16100 | NS |
| Controls MetS | 786 | 1465 | 2339 | 1897 | 128 | 7800 | |
Legend: Q1: first quartile; Q3: third quartile.